EN DE
Watch Itama Ranoraya for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Itama Ranoraya (IRRA) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Itama Ranoraya stock IDR 739, price IDR 344, upside +114.8%, quality 39 out of 100. Rating: strongly undervalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare ID · ISIN ID1000151707

IR Itama Ranoraya logo Thin data Nov 4, 2026

Itama Ranoraya

IRRA · JK
Cheap, value-trap risk

The stock costs 53% less than our calculation considers fair.

Fair value 738.81 IDR · Strongly undervalued
Low debt
Ranks above peers (8/12)
Even on cautious assumptions the value is 61% above the price (554.11 IDR).
Expensive Growth (revenue 5y +14.3 %/yr in IDR)
Thin margins · 6.3% net margin (TTM)
Quality 39/100
Negative free cash flow
Narrow moat 41/100 · thin data
Thin data
⚠ Small free float
Watch Itama Ranoraya for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

2,168 IDR 330.00 IDR Fair Value 738.81 IDR Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range 330.00 IDR – 2,168 IDR · fair‑value band 554.11 IDR – 923.51 IDR · the 344.00 IDR price screens below the 738.81 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow Itama Ranoraya in your weekly email

Every Wednesday you see whether Itama Ranoraya is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PT Itama Ranoraya Tbk wholesale trades in laboratory and pharmaceutical equipment, and medical devices for humans in Indonesia.

Show moreShow less

It offers in vitro diagnostics products comprising rapid test, serology, glucose diagnostic, NAPZA test, and clinical laboratory; medical imaging products, including bone densitometer, C-arm, flat panel digital detector, mobile and stationary x-ray, and mammography; nefrology, blood and transfusion, orthopedic, radiotherapy, and surgical products; and hospital supplies and hospital kitchen equipment.

The company also provides cold chain management, such as cold room, bloodbank, and pharmaceutical refrigerator; critical care; and pharmaceutical supplements, as well as maternal and neonatal care products. In addition, it leases office space.

It sells its products under the oneject, Abbott, Terumo, DIRUI, Medtronic, mindray, ZOLL, Sansin, Vestfrost, ASCENSIA, Hemocue, CUREXO, SATInc., PT. MEGA, Planmed, Sinmed, Balmed, KSM CARE, Trisan Care, Shamrock, OTORO, GEA, Hologic, IS, Avimac, RadmediX, and SMAM brand names.

The company was founded in 1988 and is based in Jakarta Timur, Indonesia. PT Itama Ranoraya Tbk operates as a subsidiary of PT Global Dinamika Kencana.

Stock analysis

Itama Ranoraya (IRRA) currently trades at 344.00 IDR, while our model-based Fair Value estimate is 738.81 IDR, implying the stock looks roughly 53% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 1,180 IDR per share, and 13 of the 14 models we run sit above the 344.00 IDR price.

Bear case: the Asset-Based group reads lowest at 256.76 IDR, and 1 of the 14 models stay below the price. Data coverage for this calculation is low.

Scenario range: 554.11 IDR (bear) to 923.51 IDR (bull), the price of 344.00 IDR sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Itama Ranoraya reported revenue of 1.1T IDR in FY2025 versus 1.3T IDR in FY2021, a compound −4.4%/yr. Reported net income was 65.5B IDR in FY2025, compounding −12.6%/yr from FY2021.

Key figures

Market cap 519B IDR (≈ $28.8M) Micro · P/E ratio 8.2 · P/S ratio 0.50 · EPS (TTM) 41.82 IDR · Net margin 6.3% · Return on equity 11.5% · Return on assets (EBIT) 8.2% (5-year average) · Operating margin 8.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (low confidence).

What moves the price

The share trades about 33% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 34% fair-value upside, at 115%, IRRA screens cheaper than that median.

Fair Value models

Bear 554.11 IDR Fair Value 738.81 IDR Bull 923.51 IDR
Price 344.00 IDR · Upside +114.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (35.86 IDR per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV 372.77 IDR 442.30 IDR 500.89 IDR 74
ROIC Compounder 372.77 IDR 522.17 IDR 668.93 IDR 72
Residual Income 333.40 IDR 372.97 IDR 478.43 IDR 71
All 14 models by family
Earnings-Based
Graham-Dodd 295.52 IDR 1,992 IDR 2,792 IDR 63
Lynch FV 583.79 IDR 833.98 IDR 1,084 IDR 61
PEG = 1.0 583.79 IDR 833.98 IDR 1,084 IDR 57
EPV 372.77 IDR 442.30 IDR 500.89 IDR 74
Multiples
P/E Multiple 717.08 IDR 956.11 IDR 1,195 IDR 63
P/S Multiple 554.11 IDR 738.81 IDR 923.51 IDR 58
P/B Multiple 1,003 IDR 1,338 IDR 1,672 IDR 55
EV/EBIT 350.10 IDR 633.88 IDR 917.66 IDR 63
EV/EBITDA 300.80 IDR 568.15 IDR 835.50 IDR 64
EV/Revenue 106.38 IDR 366.79 IDR 627.20 IDR 49
Asset-Based
NCAV (Graham) 191.61 IDR 256.76 IDR 383.23 IDR 54
Economic Profit
Residual Income 333.40 IDR 372.97 IDR 478.43 IDR 71
ROIC Compounder 372.77 IDR 522.17 IDR 668.93 IDR 72
Growth Earnings
Growth-Adj P/E 825.81 IDR 1,180 IDR 1,534 IDR 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 31
How much profit the company makes from its sales and capital
Quality Growth 42
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 19
Debt, balance sheet and risk of trouble
Investment 51
Does it invest with discipline instead of growing at any price?
Low Volatility 73
How calm the share price moves, does not count
Price momentum 24
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 7
Distance to the 52-week high, does not count
New shares 96
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+12.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.3%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+63.8%
What shareholders gained per year (last 5 years), in IDR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+1.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.3%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.1.3% vs 57.9%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 9%
Pace: the 5-year rate starts in 2020 (pandemic)

Watch IRRA, get fair value alerts →

Compare Itama Ranoraya with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 76 stocks

Beats the industry median on 8/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 39 · Bottom 25%
Fair Value upside +114.8% · Top 25%
Profitability
Return on equity (12 months) 11.5% · Top 25%
Return on assets 2.7% · Above median
Net margin (12 months) 6.3% · Top 25%
Operating margin (12 months) 8.9% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −15.7% · Bottom 25%
Balance sheet
Debt / equity 0.43× · Highest 25%

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/E (12 months) 8.2× · Cheapest 25%
P/B 0.90× · Cheaper than median
P/S (12 months) 0.50× · Pricier than median
EV/EBITDA 5.9× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 38
FUTURE (revenue growth)0 · sector 26
PAST (return on equity)46 · sector 28
HEALTH (low debt)78 · sector 97
DIVIDEND (yield)0 · sector 54

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Sinopharm Group 1099 HK$17.15 HK$51.45 +200% vs IRRA
Jointown Pharmaceutical Group 600998 ¥5.19 ¥11.56 +123% vs IRRA
Shanghai Pharmaceuticals Holding 601607 ¥16.54 ¥35.78 +116% vs IRRA
China National Medicines Corporation 600511 ¥29.05 ¥58.47 +101% vs IRRA
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥19.91 ¥26.64 +34% vs IRRA
Cencora, Inc COR $333.56 $341.58 +2% vs IRRA
Henry Schein, Inc HSIC $86.05 $78.69 −9% vs IRRA
McKesson Corporation MCK $1,061 $822.74 −22% vs IRRA
Galenica AG GALE CHF 90.05 CHF 61.79 −31% vs IRRA
Cardinal Health, Inc CAH $271.72 $163.14 −40% vs IRRA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Itama Ranoraya: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Itama Ranoraya Fair Value". https://www.fairvalue-calculator.com/stock/IRRA

Frequently asked questions

Is Itama Ranoraya (IRRA) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 738.81 IDR versus a price of 344.00 IDR, about +115% upside (undervalued).
What is the fair value of IRRA?
Our model-based fair value for Itama Ranoraya is 738.81 IDR (as of Nov 4, 2026), built from audited fundamentals. The current price: 344.00 IDR.
What is the quality score of IRRA?
Itama Ranoraya has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Itama Ranoraya (IRRA)?
Our model-based price target is the fair value of 738.81 IDR (as of Nov 4, 2026) from 14 valuation models. Cautious scenario 554.11 IDR, optimistic scenario 923.51 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Itama Ranoraya stock forecast for 2026?
Our models put fair value at 738.81 IDR, about +115% upside versus a price of 344.00 IDR (undervalued). Cautious scenario 554.11 IDR, optimistic scenario 923.51 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Itama Ranoraya (IRRA)?
Itama Ranoraya reported trailing-twelve-month revenue of about 1.0T IDR (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of Itama Ranoraya (IRRA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Itama Ranoraya it is 738.81 IDR per share (as of Nov 4, 2026), against a price of 344.00 IDR. It is the blended result of 14 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Itama Ranoraya stock overvalued or undervalued in 2026?
As of Nov 4, 2026, IRRA trades below its calculated fair value: price 344.00 IDR, fair value 738.81 IDR, a gap of about +115% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IRRA?
No. The price is what the market pays today (344.00 IDR); the fair value is what the company's own numbers justify (738.81 IDR). For Itama Ranoraya the two are 394.81 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Itama Ranoraya worth?
The market values Itama Ranoraya at about 519B IDR (market capitalisation, as of Nov 4, 2026). Per share that is 344.00 IDR; our models calculate a fair value of 738.81 IDR per share.
What do the bullish and bearish scenarios say about IRRA?
Our models span a range for Itama Ranoraya: cautious scenario 554.11 IDR, base 738.81 IDR, optimistic 923.51 IDR per share (as of Nov 4, 2026, price 344.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of IRRA?
Itama Ranoraya trades at a price-to-earnings ratio of 8.2 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 738.81 IDR is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2019 to 2025), reported earnings: 31.3. Other multiples: P/B 0.9, P/S 0.5, EV/EBITDA 5.9.
How solid is the balance sheet of Itama Ranoraya (IRRA)?
Balance-sheet figures for Itama Ranoraya (as of Nov 4, 2026): return on equity 11.5%, debt of 0.43 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is IRRA from its 52-week high?
Itama Ranoraya trades at 344.00 IDR, about 33% below its 52-week high of 510.00 IDR and 4% above the low of 330.00 IDR (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 738.81 IDR is for.
Which stocks are comparable to Itama Ranoraya?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Itama Ranoraya stock attractive at the current price?
The data as of Nov 4, 2026: price 344.00 IDR, calculated fair value 738.81 IDR (+115%), Quality Score 39/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IRRA calculated?
We run Itama Ranoraya through 14 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 738.81 IDR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Itama Ranoraya currently trades 53% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Itama Ranoraya (IRRA)?
The closing price on Nov 9, 2026 was 344.00 IDR. Our model-based fair value is 738.81 IDR, about +115% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Itama Ranoraya right now?
The large discount to fair value meets weak quality (39/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (554.11 IDR). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Itama Ranoraya

How large is the market capitalisation of Itama Ranoraya (IRRA)?
The market capitalisation of Itama Ranoraya is 519B IDR (≈ $28.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Itama Ranoraya (IRRA)?
The price-to-sales ratio of Itama Ranoraya is 0.50 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Itama Ranoraya (IRRA)?
Earnings per share at Itama Ranoraya are 41.82 IDR (price ÷ EPS = P/E 8.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Itama Ranoraya (IRRA)?
The net margin of Itama Ranoraya is 6.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Itama Ranoraya (IRRA)?
The return on equity (ROE) of Itama Ranoraya is 11.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Itama Ranoraya (IRRA)?
On an EBIT basis the return on assets of Itama Ranoraya is 8.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Itama Ranoraya (IRRA)?
The operating margin of Itama Ranoraya is 8.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Itama Ranoraya (IRRA)?
Revenue at Itama Ranoraya is growing −15.7% versus a year earlier (3y avg +13.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Itama Ranoraya (IRRA)?
Earnings per share at Itama Ranoraya are growing −1.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Itama Ranoraya (IRRA) generate?
The free cash flow of Itama Ranoraya is −164B IDR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Itama Ranoraya (IRRA) carry?
The net debt of Itama Ranoraya is 756B IDR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Itama Ranoraya in the live analysis

One click puts Itama Ranoraya on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.